Jiangsu Heng Rui Medicine

The drugs maker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings.

Debt pressures cast cloud over Fosun Pharma results

The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
2196.HK 600196.SHG

Recent Articles

RELATED ARTICLES

  1. Fosun International: the slim-down must go on till debts paid off
    Fosun International on cusp of new ‘asset-light’ era with latest sale
    0656.HK
  2. Fosun Tourism at crossroads as parent shops its two major assets
    1992.HK 0656.HK
  3. Fosun Tourism embarks on new journey with departure of big-name director
    1992.HK
  4. Shunned by investors, Henlius hangs up on its Hong Kong listing
    2696.HK
  5. Fosun Tourism’s post-Covid holiday fizzles
    1992.HK
  6. CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  7. CSPC Pharma taps R&D superstar in quest for new breakout drugs
    1093.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva